Supernus Pharmaceuticals, Inc.

NasdaqGM:SUPN 株式レポート

時価総額:US$1.5b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Supernus Pharmaceuticals 過去の業績

過去 基準チェック /06

Supernus Pharmaceuticalsの収益は年間平均-30.9%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 減少しています。収益は年間0.4% 10.5%割合で 増加しています。

主要情報

-30.9%

収益成長率

-31.4%

EPS成長率

Pharmaceuticals 業界の成長6.0%
収益成長率10.5%
株主資本利益率-1.7%
ネット・マージン-2.6%
前回の決算情報31 Mar 2024

最近の業績更新

Recent updates

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Apr 24
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Supernus Pharmaceuticals: Moving Through An 'Inflection Year'

Mar 04

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

May 10
We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Feb 03
Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Oct 19
These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment

Oct 10

Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio

Aug 19

Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Aug 16
Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Supernus: A Work In Progress

Jul 29

Supernus: New Beginnings

Mar 28

Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Dec 02
Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?

Nov 30
Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?

Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?

Oct 19
Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?

Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 49% Discount?

Aug 31
Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 49% Discount?

Supernus: Well Prepared For Upcoming Challenges

Aug 26

Supernus Pharmaceuticals (NASDAQ:SUPN) Seems To Use Debt Rather Sparingly

Jul 05
Supernus Pharmaceuticals (NASDAQ:SUPN) Seems To Use Debt Rather Sparingly

収支内訳

Supernus Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGM:SUPN 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 24597-1633795
31 Dec 23608133692
30 Sep 236112632986
30 Jun 236344335983
31 Mar 236685237275
31 Dec 226676137775
30 Sep 226593840578
30 Jun 226305736578
31 Mar 226017333477
31 Dec 215805330590
30 Sep 215648225187
30 Jun 2157110023485
31 Mar 2155611121291
31 Dec 2052012720176
30 Sep 2047712917778
30 Jun 2042411816278
31 Mar 2040211615273
31 Dec 1939311315369
30 Sep 1940810616165
30 Jun 1940910516269
31 Mar 1940410316472
31 Dec 1840911115589
30 Sep 183819915276
30 Jun 183598715268
31 Mar 183357314759
31 Dec 173025713850
30 Sep 172765813347
30 Jun 1725310411842
31 Mar 172289710942
31 Dec 162159110643
30 Sep 161968410139
30 Jun 16179269840
31 Mar 16163189536
31 Dec 15147148929
30 Sep 15135118425
30 Jun 1511857821
31 Mar 1511257419
31 Dec 1493-117320
30 Sep 1472-377019
30 Jun 1450-596718
31 Mar 1421-896017
31 Dec 1312-925617
30 Sep 133-834917
30 Jun 132-733922

質の高い収益: SUPNは現在利益が出ていません。

利益率の向上: SUPNは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: SUPNは利益が出ておらず、過去 5 年間で損失は年間30.9%の割合で増加しています。

成長の加速: SUPNの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: SUPNは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 19.9% ) と比較することは困難です。


株主資本利益率

高いROE: SUPNは現在利益が出ていないため、自己資本利益率 ( -1.67% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘